These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
    Author: Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D.
    Journal: Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268.
    Abstract:
    BACKGROUND/AIMS: Alteration of p53 gene links to the appearance and detection of anti-p53 antibodies in the serum. The aim of this study is to find the clinicopathologic significance for serum presence of anti-p53 antibodies in patients with colorectal carcinoma. METHODOLOGY: Serum presence of anti-p53 antibodies was examined for sera of 36 patients with colorectal carcinoma using enzyme-linked immunosorbent assay. RESULTS: Frequency of serum presence of anti-p53 antibodies was 47.2% (17 of 36). Incidence of lymph node metastasis and lymphatic invasion in tumors coexisting with serum presence of anti-p53 antibodies (70.6%, 12 of 17 and 94.1%, 16 of 17) were significantly higher than those in tumors without serum presence of anti-p53 antibodies (17.6%, 3 of 17 and 68.4%, 13 of 19; p = 0.007 and p = 0.041, respectively). Stages of the tumors were significantly more advanced in carcinomas coexisting with serum presence of anti-p53 antibodies (p = 0.023). Frequency in serum presence of anti-p53 antibodies among patients with tumors expressing p53 (73.7%, 14 of 19) was significantly higher than that among patients with tumors without p53 expression (17.6%, 3 of 17; p = 0.0005). CONCLUSIONS: Preoperative serum appearance of anti-53 antibodies can be an indicator for more malignant potential of colorectal carcinoma.
    [Abstract] [Full Text] [Related] [New Search]